FAAS
BIB icon

First Allied Advisory Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

First Allied Advisory Services’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-101
Closed -$6K – 1187
2017
Q4 		$6K Buy
+101
New +$5.7K ﹤0.01% 1483

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

First Allied Advisory Services's BIB Position: Q1 2018 in Review

First Allied Advisory Services sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2018, closing a stake of 101 shares — an estimated $6K sold.

First Allied Advisory Services first reported a position in BIB in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 41 funds tracked by Wall St. Rank hold BIB as of Q1 2018.

  • First Allied Advisory Services reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2018 after selling out during the quarter.
  • First Allied Advisory Services sold 101 ProShares Ultra NASDAQ Biotechnology shares in Q1 2018, an estimated $6K.
  • First Allied Advisory Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2017 and held it in 1 quarter.
  • First Allied Advisory Services's ProShares Ultra NASDAQ Biotechnology position peaked at $6K in Q4 2017.
  • 41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2018.

Based on First Allied Advisory Services's 13F filing for Q1 2018, filed 11 May 2018.